CGRP Forum
Send to a colleague
Register
Login
Home   |   About   |   About CGRP   |   News   |   Hot Topics   |   Trials    |   Resources   |   Contact

Just published in the New England Journal of Medicine

Fremanezumab, given monthly or quarterly, cuts headache frequency in chronic migraine

Prophylactic, subcutaneous fremanezumab, given monthly or quarterly, significantly reduces the number of monthly headache days in patients with chronic migraine, according to a phase 3 trial.

Read the full report here »

For more details on the trial design click here »


STRIVE study: erenumab once monthly reduces the impact of episodic migraine

Erenumab administered subcutaneously at a monthly dose of 70 mg or 140 mg significantly reduces migraine frequency, the effects of migraines on daily activities, and the use of acute migraine-specific medication over six months.

Read the full report here »

For more details on the trial design click here »


For an editorial comment and discussion on CGRP - the next frontier for migraine, go to: http://www.nejm.org/doi/full/10.1056/NEJMe1712559

Becoming a member is easy

Members have free open access simply by registering online.
Facebook Like us on Facebook
For the latest updates, CGRP news and analysis.
Twitter Follow us on Twitter
Hot topics, news and conference reports.
Educational Partners and Supporters (others pending) Amgen Novartis
© Copyright CGRP Forum 2017. Please click here to unsubscribe from future mailings.
‚Äč